**Kroger’s Q3 identical sales without fuel remain under pressure from cautious consumer spending and lingering headwinds.** Second-quarter results showed just 0.2% growth, weighed down by roughly 140 basis points from the Inflation Reduction Act’s pharmacy impact, plus cyclospora-related produce weakness and egg deflation. Management lowered full-year guidance to 0.2–0.8% while keeping earnings targets intact, noting Q3 should edge ahead of Q4 but will still face some residual effects and tougher year-ago comparisons. With the two leading market outcomes (0–0.5% and 0.5–1%) nearly tied, traders are pricing modest sequential improvement against ongoing macro caution and competitive pressure from discounters.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoView resolved

Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes